Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD

Bone Marrow Transplantation volume 28, pages 1097–1103 (2001)Cite this article

Abstract

The incidence of myocardial hypertrophy was determined in a comparative study of tacrolimus-based immunosuppression with cyclosporine-based immunosuppression for prevention of acute graft-versus-host disease (GVHD) after unrelated donor bone marrow transplantation. Patients were evaluated for clinical and echocardiographic abnormalities at baseline (prior to pretreatment conditioning and the first dose of study drug) and at 5–8 weeks after transplant when stable levels of oral tacrolimus or cyclosporine had been achieved. Left ventricular geometry and performance were assessed by echocardiography which included 2-D measurements and one Doppler measurement. Derived echocardiographic measurements and left ventricular mass index (LVMI) were also determined. A cut-off of <111 g/m2 was used for the upper limit of normal for LVMI. Forty-four patients were included in this study (21 tacrolimus and 23 cyclosporine), of which 31 were evaluable for a comparison with both baseline and post-transplant values. There was no significant difference in the changes from baseline for mean left ventricular mass (LVM) or LVM index (LVMI) between treatment groups. Also, within the tacrolimus group there were no significant changes for these variables from baseline to post-transplant evaluations. Within the cyclosporine group there were significant increases from baseline for mean LVM (P = 0.011) and LVMI (P = 0.007). The incidence of myocardial hypertrophy (change of LVMI from <111 g/m2 baseline to >111 g/m2 post transplant) was 20% in the tacrolimus group and 56% in the cyclosporine group (P = 0.109). Changes in the LVMI from baseline to post baseline were greater with cyclosporine than with tacrolimus therapy, and there was no evidence that tacrolimus causes myocardial hypertrophy or significant clinical changes in adult bone marrow transplant patients. The increase in LVMI after transplant in the cyclosporine group was greater than in the tacrolimus group but was not associated with any significant clinical events.

Bone Marrow Transplantation (2001) 28, 1097–1103.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate Blood 1992 80: 1838–1845

    CAS  PubMed  Google Scholar 

  2. Busuttil RW, Holt CD . Tacrolimus is superior to cyclosporine in liver transplantation (review) Transplant Proc 1998 30: 2174–2178

    Article  CAS  PubMed  Google Scholar 

  3. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors Blood 2000 96: 2062–2068

    CAS  PubMed  Google Scholar 

  4. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 1998 92: 2303–2314

    CAS  PubMed  Google Scholar 

  5. Kelly PA, Burckart GJ, Venkataramanan R . Tacrolimus: a new immuosuppressive agent (review) Am J Health Syst Pharm 1995 52: 1521–1535

    Article  CAS  PubMed  Google Scholar 

  6. Jacobson P, Uberti J, Davis W, Ratanatharathorn V . Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation (review) Bone Marrow Transplant 1998 22: 217–225

    Article  CAS  PubMed  Google Scholar 

  7. Stamnes MA, Zuker CS . Peptidyl-prolyl cis-trans isomerases, cyclophilin, FK506-binding protein, and ninaA: four of a kind (review) Curr Opin Cell Biol 1990 2: 1104–1107

    Article  CAS  PubMed  Google Scholar 

  8. Woo M, Przepiorka D, Ippoliti C et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation (review) Bone Marrow Transplant 1997 20: 1095–1098

    Article  CAS  PubMed  Google Scholar 

  9. Hodak SP, Moubarak JB, Rodriguez I et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report Transplantation 1998 66: 535–537

    Article  CAS  PubMed  Google Scholar 

  10. Atkison P, Joubert G, Barron A et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients Lancet 1995 345: 894–896

    Article  CAS  PubMed  Google Scholar 

  11. Chang RK, Alzona M, Alejos J et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation Am J Cardiol 1998 81: 1277–1280

    Article  CAS  PubMed  Google Scholar 

  12. Khanna A, Jain A, Ziady G et al. Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus Transplant Proc 1997 29: 532–533

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Baruch Y, Weitzman E, Markiewicz W et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral Transplant Proc 1996 28: 2250–2251

    CAS  PubMed  Google Scholar 

  14. Vyas S, Kumar A, Piecuch S et al. Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus Transplantation 1999 67: 490–492

    Article  CAS  PubMed  Google Scholar 

  15. Grenier FC, Luczkiw J, Bergmann M et al. A whole blood FK 506 assay for the IMx analyzer Transplant Proc 1991 23: 2748–2749

    CAS  PubMed  Google Scholar 

  16. Zucchelli GC, Pilo A, Chiesa MR et al. Progress report of an external quality assessment scheme for cyclosporine assay Therapeutic Drug Monitoring 1996 18: 273–279

    Article  CAS  PubMed  Google Scholar 

  17. Przepiorka D, Nash RA, Wingard JR et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation Biol Blood Marrow Transplant 1999 5: 94–97

    Article  CAS  PubMed  Google Scholar 

  18. Boswell GW, Bekersky I, Fay J et al. Tacrolimus pharmacokinetics in BMT patients Bone Marrow Transplant 1998 21: 23–28

    Article  CAS  PubMed  Google Scholar 

  19. Ganau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension J Am Coll Cardiol 1992 19: 1550–1558

    Article  CAS  PubMed  Google Scholar 

  20. Hertenstein B, Stefanic M, Schmeiser T et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant J Clin Oncol 1994 12: 998–1004

    Article  CAS  PubMed  Google Scholar 

  21. Uberti JP, Silver SM, Adams PT et al. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies Bone Marrow Transplant 1997 19: 1233–1238

    Article  CAS  PubMed  Google Scholar 

  22. Devine SM, Geller RB, Lin LB et al. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis Biol Blood Marrow Transplant 1997 3: 25–33

    CAS  PubMed  Google Scholar 

  23. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation Blood 1996 88: 4383–4389

    CAS  PubMed  Google Scholar 

  24. Nash RA, Pineiro LA, Storb R et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors Blood 1996 88: 3634–3641

    CAS  PubMed  Google Scholar 

  25. Brand PL, van Lingen RA, Brus F et al. Hypertrophic obstructive cardiomyopathy as a side effect of dexamethasone treatment for bronchopulmonary dysplasia Acta Paediatr 1993 82: 614–617

    Article  CAS  PubMed  Google Scholar 

  26. Dollinger MM, Plevris JN, Chauhan A et al. Tacrolimus and cardiotoxicity in adult liver transplant recipients (letter) Lancet 1995 346: 507

    Article  CAS  PubMed  Google Scholar 

  27. Antunes ML, Spotnitz HM, Clark MB et al. Long-term function of human cardiac allografts assessed by two-dimensional echocardiography J Thorac Cardiovasc Surg 1989 98: 275–284

    CAS  PubMed  Google Scholar 

  28. Lipkin GW, Tucker B, Giles M, Raine AE . Ambulatory blood pressure and left ventricular mass in cyclosporin- and non-cyclosporin-treated renal transplant recipients J Hypertension 1993 11: 439–442

    Article  CAS  Google Scholar 

  29. Przepiorka D, Blamble D, Hilsenbeck S et al. Tacrolimus clearance is age-dependent within the pediatric population Bone Marrow Transplant 2000 26: 601–605

    Article  CAS  PubMed  Google Scholar 

  30. Wallemacq PE, Furlan V, Moller A et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients Eur J Drug Metab Pharmacokinet 1998 23: 367–370

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants CA18221, CA15704, CA18029 and HL36444 from the National Institutes of Health, DHHS, Bethesda, MD. Work was also supported by Fujisawa Healthcare Inc., Deerfield, IL, and Hospital Caja de Seguro Social, Panama, Panama.

Author information

Authors and Affiliations

  1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    G Espino, T Furlong & RA Nash

  2. Department of Medicine, University of Washington, Seattle, WA, USA

    RA Nash

  3. Fujisawa Healthcare, Inc., Deerfield, IL, USA

    W Fitzsimmons

  4. Seattle Nuclear Medicine/Ultrasound Associates, Seattle, WA, USA

    J Denney

Authors
  1. G Espino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Denney
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Furlong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Fitzsimmons
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. RA Nash
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Espino, G., Denney, J., Furlong, T. et al. Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD. Bone Marrow Transplant 28, 1097–1103 (2001). https://doi.org/10.1038/sj.bmt.1703304

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703304

Keywords

Search

Advanced search

Quick links